MorphoSys AG Receives Consensus Rating of Hold from Brokerages
Slightly above 67% of MorphoSys' investor base is looking to short. The analysis of current outlook of investing in MorphoSys AG ADR suggests that many traders are alarmed regarding MorphoSys' prospects. MorphoSys' investing sentiment overview a quick insight into current market opportunities from investing in MorphoSys AG ADR. Many technical investors use MorphoSys AG ADR stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
MorphoSys |
MorphoSys AG has been given a consensus rating of Hold by the eight research firms that are currently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating on the company. The average
Read at thelincolnianonline.com
 |
MorphoSys Fundamental Analysis
We analyze MorphoSys' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MorphoSys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MorphoSys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
MorphoSys is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
MorphoSys AG ADR Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MorphoSys stock to make a market-neutral strategy. Peer analysis of MorphoSys could also be used in its relative valuation, which is a method of valuing MorphoSys by comparing valuation metrics with similar companies.
Peers
MorphoSys Related Equities
| NVCT | Nuvectis Pharma | 3.98 | ||||
| KRON | Kronos Bio | 1.06 | ||||
| IPSC | Century Therapeutics | 0.99 | ||||
| CGEM | Cullinan Oncology | 0.83 | ||||
| PCVX | Vaxcyte | 0.62 | ||||
| LYRA | Lyra Therapeutics | 0.53 | ||||
| RLYB | Rallybio Corp | 0.43 | ||||
| MLYS | Mineralys Therapeutics, | 0.00 | ||||
| EWTX | Edgewise Therapeutics | 0.00 | ||||
| PMVP | Pmv Pharmaceuticals | 0.00 | ||||
| REPL | Replimune | 0.00 | ||||
| MRSN | Mersana Therapeutics | 0.00 | ||||
| GBIO | Generation Bio | 0.00 | ||||
| IMCR | Immunocore Holdings | 0.48 | ||||
| ELVN | Enliven Therapeutics | 0.94 | ||||
| ACLX | Arcellx | 1.52 | ||||
| GLUE | Monte Rosa | 2.22 | ||||
| GOSS | Gossamer Bio | 2.36 | ||||
| CCCC | C4 Therapeutics | 2.64 | ||||
| IMRX | Immuneering Corp | 3.86 | ||||
| VTYX | Ventyx Biosciences | 6.30 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in MorphoSys Stock
If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |